Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community

摘要

BackgroundStrongyloides seroprevalence is hyper-endemic in many Australian Aboriginal and Torres Strait Islander communities, ranging from 35–60%. We report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community.